X0306 4 2022-10-03 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001785732 Stock Elyse C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false true false false Chief Medical Officer Common Shares 2022-10-03 4 D false 11090.00 148.50 D 0.00 D Common Shares 2022-10-03 4 D false 5374.00 148.50 D 0.00 I By Spouse Restricted Share Unit Award 2022-10-03 4 D false 9750.00 D Common Shares 9750.00 0.00 D Restricted Share Unit Award 2022-10-03 4 D false 7500.00 D Common Shares 7500.00 0.00 D Restricted Share Unit Award 2022-10-03 4 D false 3375.00 D Common Shares 3375.00 0.00 D Restricted Share Unit Award 2022-10-03 4 D false 3000.00 D Common Shares 3000.00 0.00 I By Spouse Restricted Share Unit Award 2022-10-03 4 D false 2500.00 D Common Shares 2500.00 0.00 I By Spouse Restricted Share Unit Award 2022-10-03 4 D false 938.00 D Common Shares 938.00 0.00 I By Spouse Stock Options (Right to Buy) 125.69 2022-10-03 4 D false 775.00 D 2032-01-07 Common Shares 775.00 0.00 D Stock Options (Right to Buy) 125.69 2022-10-03 4 D false 25225.00 D 2032-01-07 Common Shares 25225.00 0.00 D Stock Options (Right to Buy) 81.32 2022-10-03 4 D false 2398.00 D 2031-01-06 Common Shares 2398.00 0.00 D Stock Options (Right to Buy) 81.32 2022-10-03 4 D false 27602.00 D 2031-01-06 Common Shares 27602.00 0.00 D Stock Options (Right to Buy) 55.99 2022-10-03 4 D false 25000.00 D 2029-11-25 Common Shares 25000.00 0.00 D Stock Options (Right to Buy) 49.60 2022-10-03 4 D false 6000.00 D 2029-03-22 Common Shares 6000.00 0.00 D Stock Options (Right to Buy) 31.62 2022-10-03 4 D false 45666.00 D 2028-11-20 Common Shares 45666.00 0.00 D Stock Options (Right to Buy) 31.62 2022-10-03 4 D false 3084.00 D 2028-11-20 Common Shares 3084.00 0.00 D Stock Options (Right to Buy) 20.28 2022-10-03 4 D false 1180.00 D 2027-12-06 Common Shares 1180.00 0.00 D Stock Options (Right to Buy) 20.28 2022-10-03 4 D false 10358.00 D 2027-12-06 Common Shares 10358.00 0.00 D Stock Options (Right to Buy) 36.62 2022-10-03 4 D false 10000.00 D 2027-09-04 Common Shares 10000.00 0.00 D Stock Options (Right to Buy) 50.85 2022-10-03 4 D false 7500.00 D 2029-12-18 Common Shares 7500.00 0.00 I By Spouse Stock Options (Right to Buy) 46.16 2022-10-03 4 D false 8452.00 D 2029-09-16 Common Shares 8452.00 0.00 I By Spouse Stock Options (Right to Buy) 46.16 2022-10-03 4 D false 2548.00 D 2029-09-16 Common Shares 2548.00 0.00 I By Spouse Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. /s/ George Clark, Attorney-in-Fact 2022-10-03